With continuous investment in research and development, Livzon Pharmaceutical's innovative pipeline is steadily delivering on its promises.
It is reported that on August 27, the website of the National Medical Products Administration showed that Livzon Pharmaceutical's Class 1 new drug, Lyconcitazone, was approved for marketing through the priority review and approval process.
Lyconchitab is a dual-target inhibitor of IL-17A/F, which simultaneously blocks the interaction between IL-17A/F and its receptor, thereby inhibiting downstream inflammatory signaling pathways. It is indicated for multiple autoimmune and inflammatory diseases. This product has been approved for adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy. The announcement indicates that psoriasis is an inflammatory skin disease prone to relapse, induced by both genetic and environmental factors. There are approximately 125 million patients worldwide, with over 7 million in China, of whom plaque psoriasis accounts for about 80%.
It is understood that after its approval, Lyconchitab has become the world's second and China's first IL17A/F dual-target inhibitor, officially entering the domestic IL-17 competitive arena with its differentiated advantages.
The world's first approved dual-target inhibitor of IL-17A/F is UCB's bicizumab, which targets both IL-17A and IL-17F. Currently, this product is approved for multiple indications, including plaque psoriasis, ankylosing spondylitis, and hidradenitis suppurativa. Data shows that the drug saw rapid sales growth after its launch, with sales reaching $2.519 billion in 2025, a year-on-year increase of 285%.
In addition to being approved for the treatment of plaque psoriasis, Livzon Pharmaceutical's Leconchitab is also being developed for the treatment of ankylosing spondylitis. For example, in December 2024, the Phase III clinical trial of the drug for the treatment of ankylosing spondylitis reached its endpoint; in May 2026, the marketing application for the relevant indication was accepted by the CDE ... The future market prospects are broad.
According to public information, Livzon Pharmaceutical Group is a large-scale comprehensive pharmaceutical group covering pharmaceutical R&D, production, and commercialization. To continuously improve its innovation capabilities and accelerate its transformation and upgrading, Livzon Pharmaceutical Group has been continuously increasing its R&D investment. Data shows that the company's R&D investment reached 382 million yuan in the first half of this year. With this sustained R&D investment, many of the company's core products entered critical stages of clinical development, market review, and approval in the first half of the year, accelerating the implementation of innovative R&D achievements.
In the field of gastrointestinal tract, for example, Livzon Pharmaceutical Group has made new progress in the research and development of its potassium competitive acid blocker (P-CAB) series drugs JP-1366. Among them, the indication for JP-1366 tablets for reflux esophagitis is under market review. The drug, in combination with antibiotics for the indication of Helicobacter pylori (Hp) eradication, has successfully completed the first patient dosing in a Phase III clinical trial and is accelerating the "head-to-head" non-inferiority pivotal trial. The indication for injectable JP-1366 for peptic ulcer bleeding has been initiated in a Phase III clinical trial.
In the field of assisted reproduction, the company's recombinant human follicle-stimulating hormone injection (pen) was approved for marketing in June 2026. Phase III clinical trials for the oral GnRH antagonist LPM7100328 capsules for assisted reproduction have been initiated. Phase III clinical trials for the injectable triptorelin acetate microspheres for central precocious puberty are nearing completion. Injectable leuprorelin acetate microspheres (3M) are in the marketing application review stage and are expected to be approved for marketing within the year.
In the field of neuropsychiatry, Livzon Pharmaceutical Group's injectable birepiperazole microspheres have initiated a Phase I clinical trial, and the first participant was successfully dosed in July. The Phase II clinical trial of NS-041 tablets (a KCNQ2/3 potassium channel opener), a Class 1 innovative chemical drug with a novel anti-epileptic mechanism, is progressing steadily, with over 140 patients already enrolled. Furthermore, the company's Class 1.1 innovative traditional Chinese medicine, LZZN1801, for vestibular migraine, has submitted an IND application in June 2026…
From the successful launch of a Class 1 new drug in the autoimmune field to the simultaneous development of its digestive, reproductive, and neuropsychiatric pipelines, Livzon Pharmaceutical's innovative transformation has gradually moved from pipeline development to commercialization. With continued R&D investment, several candidate drugs are expected to achieve breakthroughs, bringing more high-quality domestically produced new drugs to Chinese patients and opening up long-term growth opportunities for the company.

https://mp.weixin.qq.com/s?__biz=MzU5NjUwOTgyNg==&mid=2247726102&idx=3&sn=a604ce014c52ddf258bd4cf0c9bdadf7&chksm=ff3317dbd105b2257a846cc2fff57d355b5f06346611ccb2d5b8d8279f326b8dc688bb32972c&scene=126&sessionid=0#rd